Heritage Investors Management Corp decreased its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 85,733 shares of the company’s stock after selling 3,335 shares during the period. Heritage Investors Management Corp’s holdings in Teva Pharmaceutical Industries were worth $1,847,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. PointState Capital LP purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $161,826,000. Point72 Asset Management L.P. purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $90,746,000. Renaissance Technologies LLC raised its position in Teva Pharmaceutical Industries by 348.1% during the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock valued at $98,177,000 after purchasing an additional 3,135,900 shares in the last quarter. Beck Mack & Oliver LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $64,484,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in Teva Pharmaceutical Industries by 116.1% during the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,354,508 shares of the company’s stock valued at $57,262,000 after purchasing an additional 1,264,900 shares in the last quarter. 65.10% of the stock is owned by institutional investors.
In related news, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the transaction, the vice president now owns 2,488 shares in the company, valued at approximately $58,940.72. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the transaction, the insider now owns 2,376 shares in the company, valued at approximately $56,334.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,531 shares of company stock worth $152,749. 0.43% of the stock is owned by company insiders.
TEVA has been the topic of a number of research reports. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target on the stock in a research report on Monday, October 1st. Credit Suisse Group downgraded Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $23.00 in a research report on Friday, September 7th. Leerink Swann upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and raised their price target for the company from $16.00 to $24.00 in a research report on Monday, October 1st. Cantor Fitzgerald set a $25.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, September 14th. Finally, Mizuho raised their price target on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 17th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus target price of $21.58.
TEVA opened at $23.45 on Friday. The stock has a market capitalization of $23.48 billion, a PE ratio of 5.97, a P/E/G ratio of 7.08 and a beta of 0.77. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. Teva Pharmaceutical Industries Ltd has a 12 month low of $11.44 and a 12 month high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.54 billion. During the same quarter in the previous year, the business earned $1.00 earnings per share. The company’s quarterly revenue was down 19.4% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post 2.78 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Ltd (TEVA) Shares Sold by Heritage Investors Management Corp” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-heritage-investors-management-corp.html.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Stop Order Uses For Individual Investors
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.